CMS-D001 / China Medical System - LARVOL DELTA

A multicenter, randomized, double-blind, placebo-controlled phase Ib clinical study assessing the efficacy and safety of CMS-D001 in patients with moderate to severe plaque psoriasis. (ChiCTR) - P1 | N=60 | Not yet recruiting | Sponsor: China-Japan Friendship Hospital; Hainan Dermavon Pharmaceutical Technology Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis

IND Approval: CMS’s Self-developed Innovative Drug Highly Selective TYK2 Inhibitor CMS-D001 is Approved for Drug Clinical Trials for Atopic Dermatitis Indication (CMS Press Release) - "China Medical System Holdings Limited (the 'Group' or 'CMS') is pleased to announce that innovative drug CMS-D001 tablets ('CMS-D001')...has been granted approval for drug clinical trials by National Medical Products Administration of the People’s Republic of China ('NMPA') on 11 July 2025. The NMPA grants the consent to conduct a clinical trial evaluating the safety and efficacy of CMS-D001 for the treatment of atopic dermatitis (AD)."

New trial • Atopic Dermatitis

A randomized, double-blind, placebo-controlled, single or multiple dose escalation and food effect (open) Phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of CMS-D001 in healthy subjects (ChiCTR) - P1 | N=80 | Recruiting | Sponsor: Wuhan Jinyintan Hospital (Wuhan Infectious Disease Hospital); Hainan Kangzhe Beauty Technology Co., Ltd.

New P1 trial • Dermatology • Immunology • Psoriasis